๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Recurrent or Refractory Solid Tumors

Study in Children and Adolescents of 177Lu-DOTATATE (Lutatheraยฎ) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site๐Ÿ“ Boadilla del Monte Fundaciรณn de investigaciรณn HM ยท Tests: Olaparib; 177Lu-DOTATATE IMA402 T Cell-Engaging Receptor Molecule (TCERยฎ) in Recurrent and/or Refractory Solid Tumors NCT05958121Phase 1, Phase 229 sites๐Ÿ“ Heidelberg๐Ÿ“ Heidelberg๐Ÿ“ Mannheim Immatics Biotechnologies GmbH ยท Tests: IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy, IMA402 and IMA401, IMA402 and monoclonal antibody Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites๐Ÿ“ Tucson๐Ÿ“ New Haven๐Ÿ“ Baltimore Calico Life Sciences LLC ยท Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deatโ€ฆ Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors NCT06320405Phase 1, Phase 21 site๐Ÿ“ Portland OHSU Knight Cancer Institute ยท Tests: Axatilimab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging ML-016 in Advanced Cancer With Lung and/or Liver Involvement NCT07723482Phase 1, Phase 23 sites๐Ÿ“ Miranda๐Ÿ“ Wollongong๐Ÿ“ Buderim BrYet US, Inc. ยท Tests: ML-016 APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors NCT05701306Phase 1, Phase 23 sites๐Ÿ“ Guangzhou๐Ÿ“ Wuhan๐Ÿ“ Tianjin Ascentage Pharma Group Inc. ยท Tests: APG-115, APG-2575 ACTengineยฎ IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors NCT03686124Phase 1, Phase 221 sites๐Ÿ“ Stanford๐Ÿ“ Aurora๐Ÿ“ Miami Immatics US, Inc. ยท Tests: IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab, IMADetectยฎ Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors NCT03934372Phase 1, Phase 223 sites๐Ÿ“ Ghent๐Ÿ“ Paris๐Ÿ“ Paris Incyte Biosciences International Sร rl ยท Tests: Ponatinib A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors NCT06063681Phase 13 sites๐Ÿ“ Randwick๐Ÿ“ Clayton๐Ÿ“ Frankston Stingray Therapeutics ยท Tests: SR-8541A, Immune checkpoint inhibitor (ICI) IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Becotatug Vedotin Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors NCT06132503Phase 11 site๐Ÿ“ West Valley City Lantern Pharma Inc. ยท Tests: LP-284 Combination of CAR-DC Vaccine and ICIs in Malignant Tumors NCT05631886Phase 11 site๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide, anti-PD-1 antibody, Anti-CTLA4 Monoclonal Antibody Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer NCT07589543Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DUALNK, Cyclophosphamide, Fludarabine Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors NCT06234098Phase 1, Phase 29 sites๐Ÿ“ Scottsdale๐Ÿ“ Bakersfield๐Ÿ“ El Segundo Alyssum Therapeutics ยท Tests: AT-1965 Liposome Injection A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment NCT04928677Phase 15 sites๐Ÿ“ Los Angeles๐Ÿ“ Atlanta๐Ÿ“ Boston Memorial Sloan Kettering Cancer Center ยท Tests: Codrituzumab Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma NCT07502287Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DTNB-NK, Fludarabine, Cyclophosphamide Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors NCT05533697Phase 1, Phase 239 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Aurora ModernaTX, Inc. ยท Tests: mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer NCT06184035Phase 1, Phase 22 sites๐Ÿ“ Adelaide๐Ÿ“ Melbourne Spago Nanomedical AB ยท Tests: [177Lu]Lu-SN201 PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors NCT06721689Phase 1, Phase 27 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Boston Theodore Laetsch ยท Tests: PEEL-224, Vincristine, Temozolomide (TMZ) FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma NCT06865664Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: fludarabine, cyclophosphamide, cetuximab, FGFR4-CAR T Cells A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors NCT05985161Phase 216 sites๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto๐Ÿ“ Washington D.C. Memorial Sloan Kettering Cancer Center ยท Tests: Selinexor Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345Phase 16 sites๐Ÿ“ Orlando๐Ÿ“ Boston๐Ÿ“ Oklahoma City Sutro Biopharma, Inc. ยท Tests: STRO-006, Pembrolizumab A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. NCT07389239Phase 1, Phase 21 site๐Ÿ“ Chicago University of Chicago ยท Tests: Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFฮฒRII, Aldesleukin Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702Phase 1, Phase 210 sites๐Ÿ“ Palo Alto๐Ÿ“ Aurora๐Ÿ“ Washington D.C. St. Jude Children's Research Hospital ยท Tests: Onivyde, Talazoparib, Temozolomide A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors NCT04794972Phase 16 sites๐Ÿ“ Beijing๐Ÿ“ Chongqing๐Ÿ“ Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: GNC-039 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors NCT04119024Phase 13 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Stanford Anusha Kalbasi ยท Tests: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119Phase 1, Phase 221 sites๐Ÿ“ Birmingham๐Ÿ“ Los Angeles๐Ÿ“ Orange Children's Oncology Group ยท Tests: Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma. NCT07779798Phase 14 sites๐Ÿ“ Duarte๐Ÿ“ Tampa๐Ÿ“ Houston Crossbow Therapeutics, Inc. ยท Tests: CBX-663
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy